No Data
Express News | JPMorgan Chase & Co's Long Position in Beigene Decreases to 9.83% on Jan 3 From 10.33% - HKEX
Beigene Insider Sold Shares Worth $7,370,515, According to a Recent SEC Filing
Indaptus Therapeutics Provides 2025 Outlook, Launching Decoy20 Combination Cohort With BeiGene's Tislelizumab, Expanding Clinical Sites Beyond 8, Updating Higher Dose Cohort, First Patient Dosed In Combination, Focus On Cancer Challenges
BeiGene Issues Overseas Regulatory Announcement on Form 10-K/A Amendment
10-K/A: Annual report (Amendment)
[Brokerage Focus] CMB International stated that the pharmaceutical industry is expected to outperform the market in 2025, benefiting from overseas interest rate cuts and improvements in the domestic macro environment.
Jinwu Finance News | Zh Xia International released a Research Report stating that on January 3, the General Office of the State Council issued the "Opinions on Deepening the Reform of Pharmaceutical and Medical Instruments Regulation to Promote High-Quality Development of the Pharmaceutical Industry." The policy mentions deepening the reform of the entire process of pharmaceutical and medical instruments regulation, accelerating the establishment of a unified national market in the field of pharmaceutical and medical instruments, creating an innovative ecosystem with Global competitiveness, and promoting the transition of China from a major pharmaceutical country to a strong pharmaceutical country. The policy aims for significant improvements in the quality and efficiency of the review and approval of Innovative Drugs and medical instruments by 2027, establishing a regulatory system that aligns with pharmaceutical innovation and industrial development. By 2035, the pharmaceutical industry will have...
